Journal
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 61, Issue 4, Pages -Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.02399-16
Keywords
Mycobacterium; tuberculosis; MmpL3; mycolic acids; drug synergism; Mycobacterium tuberculosis
Categories
Funding
- National Institutes of Health/National Institute of Allergy and Infectious Diseases [AI116525]
- Global Alliance for TB Drug Development
Ask authors/readers for more resources
A number of inhibitors of the essential Mycobacterium tuberculosis mycolic acid transporter, MmpL3, are currently under development as potential novel antituberculosis agents. Using the checkerboard method to study the interaction profiles of various antituberculosis drugs or experimental compounds with two different chemotypes inhibiting this transporter (indolcarboxamides and adamantyl ureas), we showed that MmpL3 inhibitors act synergistically with rifampin, bedaquiline, clofazimine, and beta-lactams.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
